Comparative in vitro degradation of the human hemorphin LVV-H7 in mammalian plasma analysed by capillary zone electrophoresis and mass spectrometry

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 2, 2007, Pages 73-85

  John, Harald ^a,c   Schulz, Stefanie ^a   Forssmann, Wolf Georg ^b  

^a IPF PHARMACEUTICALS GMBH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c BUNDESWEHR INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (Germany)

Author keywords

Aminopeptidase M; Angiotensin converting enzyme; CZE UV; Hemorphin; LVV H7; MALDI TOF MS

Indexed keywords

ACTINONIN; ALPHA CYANO 4 HYDROXYCINNAMIC ACID; AMASTATIN; APROTININ; ARPHAMENINE A; ARPHAMENINE B; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL PEPTIDASE IV; DRUG METABOLITE; EBELACTONE A; EBELACTONE B; HYDROXYPROPYLMETHYLCELLULOSE; LEUCYLVALYLVALYLHEMORPHIN 7; LEUCYLVALYLVALYLTYROSYLPROLYLTRYPTOPHANYLTHREONYLGLUTAMINE; LEUHISTIN; MICROSOMAL AMINOPEPTIDASE; MU OPIATE RECEPTOR AGONIST; PHEBESTIN; PHOSPHORAMIDON; PROTEINASE INHIBITOR; THROMBIN; TRYPTOPHANYLTHREONYLGLUTAMYLARGINYLPHENYLALANINE; TYROSYLPROLYLTRYPTOPHANYLTHREONYLGLUTAMINE; TYROSYLPROLYLTRYPTOPHANYLTHREONYLGLUTAMYLARGINYLPHENYLALANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALYLTYROSYLPROLYLTRYPTOPHANYLTHREONYLGLUTAMINE; VALYLTYROSYLPROLYLTRYPTOPHANYLTHREONYLGLUTAMYLARGINYLPHENYLALANINE; VALYLVALYLTYROSYLPROLYLTRYPTOPHANYLTHREONYLGLUTAMINE; VALYLVALYLTYROSYLPROLYLTRYPTOPHANYLTHREONYLGLUTAMYLARGINYLPHENYLALANINE;

AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD ANALYSIS; CAPILLARY ZONE ELECTROPHORESIS; CARBOXY TERMINAL SEQUENCE; COMPARATIVE STUDY; DRUG DEGRADATION; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; MAMMAL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; RAT; SPECIES DIFFERENCE;

ANIMALS; ANTICOAGULANTS; ANTIGENS, CD13; BIOTRANSFORMATION; CAPILLARY ELECTROCHROMATOGRAPHY; CITRATES; EDETIC ACID; HEMOGLOBINS; HEPARIN; HUMANS; HYDROGEN-ION CONCENTRATION; MASS SPECTROMETRY; PEPTIDE FRAGMENTS; REFERENCE STANDARDS; SPECIES SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 33947380595     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.533     Document Type: Article

References (52)

1. Garreau I, Cucumel K, Daguoassat N, Zhao Q, Cupo A, Piot JM. Hemorphin peptides are released from hemoglobin by cathepsin D. Radioimmunoassay against the C-part of V-V-hemorphin-7: an alternative assay for the cathepsin D activity. Peptides 1997; 18: 293-300.
2. Fruitier I, Garreau I, Piot JM. Cathepsin D is a good candidate for the specific release of a stable hemorphin from hemoglobin in vivo: VV-hemorphin-7. Biochem Biophys Res Common 1998; 246: 719-724.
3. Sanderson Nydahl K, Pierson J, Nyberg F, Caprioli RM, Andren PE. In vivo processing of LVV-hemorphin-7 in rat brain and blood utilizing microdialysis combined with electrospray mass spectrometry. Rapid Commun Mass Spectrom 2003; 17: 838-844.
4. Cerpa-Poljak A, Lahnstein J, Mason KE, Smythe GA, Duncan MW. Mass spectrometric identification and quantification of hemorphins extracted from human adrenal and pheochromocytoma tissue. J Neurochem 1997; 68: 1712-1719.
5. Lammerich HP, Busmann A, Kutzleb Ch, et al. Identification and functional characterization of hemorphins VV-H7 and LVV-H-7 as low-affinity agonists for the orphan bombesin receptor subtype 3. Br J Pharmacol 2003; 138: 1431-1440.
6. Nyberg F, Sanderson K, Glämsta EL. The hemorphins: a new class of opioid peptides derived from the blood protein haemoglobin. Biopolymers 1997; 43: 147-156.
7. Cohen M, Fruitier-Arnaudin I, Sauvan R, Birnbaum D, Piot JM. Serum levels of hemorphin-7 peptides in patients with breast cancer. Clin Chim Acta 2003; 337: 59-67.
8. Poljak A, McLean CA, Sachdev P, Brodaty H, Smythe GA. Quantification of hemorphins in Alzheimer's disease brains. J Neurosci Res 2004; 75: 704-714.
9. 4 receptor ligand and inhibitor of insulin-regulated aminopeptidase. J Pharmacol Exp Ther 2003; 305: 205-211.
10. Albiston AL, Pederson ES, Burns P, et al. Attenuation of scopolamine-induced learning deficits by LVV-hemorphin-7 in rats in the passive avoidance and water maze paradigms. Behav Brain Res 2004; 154: 239-243.
11. Albiston AL, Fernando R, Ye S, Peck GR, Chai SY. Alzheimeŕs, angiotensin IV and an aminopeptidase. Biol Pharm Bull 2004; 27: 765-767.
12. 4) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 2001; 276: 48623-48626.
13. Zhou D, Li F. Protein binding study of clozapine by capillary electrophoresis in the frontal analysis mode. J Pharm Biomed Anal 2004; 35: 879-885.
14. Hayakari M, Satoh K, Izumi H, et al. Kinetic-controlled hydrolysis of Leu-Val-Val-hemorphin-7 catalyzed by angiotensin-converting enzyme from rat brain. Peptides 2003; 24: 1075-1082.
15. Lantz I, Glämsta EL, Talbäck L, Nyberg F. Hemorphins derived from hemoglobin have an inhibitory action on angiotensin converting enzyme activity. FEBS Lett 1991; 287: 39-41.
16. Moisan S, Harvey N, Beaudry C, et al. Structural requirements and mechanism of the pressor activity of Leu-Val-Val-hemorphin-7, a fragment of hemoglobin β-chain in rats. Peptides 1998; 19: 119-131.
17. Sanderson K, Andren PE, Caprioli RM, Nyberg F. In vitro metabolism of LVV-hemorphin-7 in human plasma studied by reversed-phase high-performance liquid chromatography and micro-electrospray mass spectrometry. J Chromatogr A 1996; 743: 207-212.
18. Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, May 2001.
19. John H, Huynh KD, Hedtmann Ch, et al. In vitro degradation of the antimicrobial human peptide HEM-γ 130-146 in plasma analyzed by a validated quantitative LC-MS/MS procedure. Anal Biochem 2005; 341: 173-186.
20. Skoog B, Wichman A. Calculation of the isoelectric points of polypeptides from the amino acid composition. Trends Anal Chem 1986; 5: 82-83.
21. Adamson N, Riley PF, Reynolds EC. The analysis of multiple phosphoseryl-containing casein peptides using capillary zone electrophoresis. J Chromatogr 1993; 646: 391-396.
22. Verzola B, Chiti F, Manao G, Righetti PG. Monitoring equilibria and kinetics of protein folding/unfolding reactions by capillary zone electrophoresis. Anal Biochem 2000; 282: 239-244.
23. Ban E, Choi OK, Chung WY, et al. Influence of buffer composition and sample pre-treatment on efficiency separation for monitoring neuropeptides in plasma using capillary electrophoresis. Electrophoresis 2001; 22: 2173-2178.
24. Lendeckel U, Wex T, Reinhold D, et al. Induction of the membrane alanyl-aminopeptidase gene and surface expression in human T-cells by mitogenic activation. Biochem J 1996; 319: 817-821.
25. Nagai M, Kojima F, Naganawa H, Hamada M, Aoyagi T, Takeuchi T. Phebestin, a new inhibitor of aminopeptidase N, produced by Streptomyces sp. MJ716-m3. J Antibiot 1997; 50: 82-84.
26. Hewlett G. Apropos aprotinin: a review. Nature Biotechnol 1990; 6: 565-568.
27. Umezawa H, Aoyagi T, Ohuchi S, et al. Arphamenines A and B, new inhibitors of aminopeptidase B, produced by bacteria. J Antibiot 1983; 36: 1572-1575.
28. Saito M, Aoyaki T, Umezawa H, Nagai Y. Bestatin, a new specific inhibitor of aminopeptidases, enhances activation of small lymphocytes by concanavalin A. Biochem Biophys Res Commun 1977; 76: 526-533.
29. Aoyagi T, Yoshida S, Matsuda N, Ikeda T, Hamada M, Takeuchi T. Leuhistin, a new inhibitor of aminopeptidase M, produced by Bacillus laterosporus BMI156-14F1, I. Taxonomy, production, isolation, physico-chemical properties and biological activities. J Antibiot 1991; 44: 573-578.
30. Zhang L, Edwards DG, Berecek KH. Effects of early captopril treatment and its removal on plasma angiotensin-converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY). Clin Exp Hypertens 1996; 18: 201-226.
31. Uotani K, Naganawa H, Aoyagi I, Umezawa H. Biosynthetic studies of ebelactone A and B by 13C NMR spectrometry. J Antibiot 1982; 35: 1670-1674.
32. Yoshida S, Naganawa H, Aoyagi T, Takeuchi T. Leuhistin, a new inhibitor of aminopeptidase M, produced by Bacillus laterosporus BMI156-14F1, II. Structure determination of leuhistin. J Antibiot 1991; 44: 579-581.
33. Komiyama T, Aoyagi T, Takeuchi T, Umezawa H. Inhibitory effects of phosphoramidon on neutral metalloendopeptidases and its application on affinity chromatography. Biochem Biophys Res Commun 1975; 65: 352-357.
34. 2Cl-A selective affinity label for thrombin. Thromb Res 1979; 14: 969-973.
35. Lendeckel U, Kähne T, Arndt M, Frank K, Ansorge S. Inhibition of alanyl aminopeptidase induces MAP-kinase p42/ERK2 in the human T cell line KARPAS-299. Biochem Biophys Res Commun 1998; 252: 5-9.
36. Yoshida S, Aoyagi T, Takeuchi T. Biosynthetic study of leuhistin, a new inhibitor of aminopeptidase M. J Antibiot 1991; 44: 683-684.
37. Xu Y, Lai LT, Gabrilove JL, Scheinberg DA. Antitumor activity of actinonin in vitro and in vivo. Clin Cancer Res 1998; 4: 171-176.
38. Sayama K, Goto Y, Iguchi T, Takeda Y, Matsuzawa A. Effects of an antibiotic protease inhibitor, actinonin on the growth within collagen gels of non-metastatic and metastatic mouse mammary tumors of the same origin. Cancer Lett 1995; 94: 171-177.
39. Razak K, Newland AC. The significance of aminopeptidases and haematopoietic cell differentiation. Blood Rev 1992; 6: 243-250.
40. Tokioka-Terao M, Hiwada K, Kokubu T. Purification and characterization of aminopeptidase N from human plasma. Enzyme 1984; 32: 65-75.
41. Favaloro EJ, Browning T, Facey D. CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated. Exp Hematol 1993; 21: 1695-1701.
42. Balogh A, Cadel S, Foulon T, et al. Aminopeptidase B: a processing enzyme secreted and associated with the plasma membrane of rat pheochromocytoma (PC12) cells. J Cell Sci 1998; 111: 161-169.
43. Garreau I, Chansel D, Vandermeersch S, Fruitier I, Piot JM, Ardaillou R. Hemorphins inhibit angiotensin IV binding and interact with aminopeptidase N. Peptides 1998; 19: 1339-1348.
44. http://www.expasy.org/uniprot/P15144 (May 2006)
45. Amoscato AA, Alexander JW, Babcock GF. Surface aminopeptidase activity of human lymphocytes. J. Biochemical and biologic properties of intact cells. J Immunol 1989; 142: 1245-1252.
46. Bramucci M, Miano A, Quassinti L, Maccan E, Murri O, Amici D. Degradation of thymic humoral factor γ2 by human plasma: involvement of angiotensin converting enzyme. Regul Pept 2003; 111: 199-205.
47. Ling TY, Chen CL, Huang YH, Liu IH, Huang SS, Huang JS. Identification and characterization of the acidic pH binding sites for growth regulatory ligands of low density lipoprotein receptor-related protein-1. J Biol Chem 2004; 279: 38736-38748.
48. van den Bongard HJGD, Kemper EM, van Tellingen O, et al. Development and validation of a method to determine the unbound paclitaxel fraction in human plasma. Anal Biochem 2004; 324: 11-15.
49. Mark S, Kübler B, Höning S, et al. Diversity of human insulin-like growth-factor (IGF) binding protein-2 fragments in plasma: primary structure, IGF-binding properties, and disulfide bonding pattern. Biochemistry 2005; 44: 3644-3652.
50. Venturelli F, Roscetti G, Roda LG. Mechanisms protecting plasma peptides from enzyme hydrolysis: a comparative study. Comp Biochem Physiol B 1987; 87: 485-488.
51. Venturelli F, Roscetti G, Possenti R, Vita F, Roda LG. Peripheral enkephalin hydrolysis in different animal species: a comparative study. Neurochem Res 1985; 10: 333-342.
52. Shibanoki S, Weinberger SB, Schulteis C, Ishikawa K, Martinez Jr JL. Enkephalin hydrolysis by mouse plasma in vitro. Life Sci 1992; 50: 667-675.